MiMedx to Acquire Sanara MedTech in $350M Deal — MiMedx Group, Inc.

Event summary

MiMedx will acquire Sanara MedTech for $350M in a cash and stock deal valued at $35 per share.
The transaction is expected to close by the end of 2026, subject to regulatory approvals and shareholder votes.
Combined revenue for 2027 is projected to exceed $400M with an adjusted EBITDA margin over 20%.
MiMedx expects over $20M in run-rate cost synergies from the acquisition.

The big picture

This acquisition positions MiMedx as a leader in regenerative medicine solutions for the operating room, expanding its product offerings and commercial reach. The deal reflects a broader trend of consolidation in the medical technology sector, driven by the need to achieve economies of scale and diversify revenue streams. With projected combined revenues exceeding $400M and significant cost synergies, the transaction underscores MiMedx’s strategic priority to accelerate growth in surgical markets.

What we're watching

Integration Challenges: The pace at which MiMedx and Sanara can integrate their operations will determine the realization of anticipated synergies.
Regulatory Approvals: Whether the transaction receives timely regulatory approvals could impact the expected closing timeline by year-end 2026.
Market Expansion: How effectively MiMedx leverages Sanara’s commercial scale to expand its surgical footprint across multiple subspecialties.